Format

Send to

Choose Destination
Cardiovasc Res. 2018 Aug 1;114(10):1273-1280. doi: 10.1093/cvr/cvy147.

Metabolic changes in hypertrophic cardiomyopathies: scientific update from the Working Group of Myocardial Function of the European Society of Cardiology.

Author information

1
Amsterdam UMC, Vrije Universiteit Amsterdam, Physiology, Amsterdam Cardiovascular Sciences, De Boelelaan 1117, 1081 HV Amsterdam, The Netherlands.
2
Netherlands Heart Institute, Utrecht, The Netherlands.
3
Department of Translational Medical Sciences, Federico II University, Naples, NA, Italy.
4
Department of Cardiology, Maastricht University Medical Center & CARIM, Maastricht University, Maastricht, The Netherlands.
5
Molecular Cardiology, Department of Cardiology and Angiology, Medical School Hannover, Germany.
6
Department of Systems Physiology, Ruhr University Bochum, Bochum, Germany.
7
Department of Surgery and Physiology, Faculty of Medicine, Cardiovascular Research Centre, University of Porto, Porto, Portugal.
8
The James Black Centre & King's British Heart Foundation Centre, King's College, University of London, London, UK.
9
Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany.
10
National Heart and Lung Institute, Imperial College London, London, UK.
11
REBIRTH Excellence Cluster, Hannover Medical School, Hannover, Germany.
12
School of Medicine & Dentistry, University of Aberdeen, Aberdeen AB25 2ZD, UK.
13
Pole of Pharmacology and Therapeutics, Institut de Recherche Experimentale et Clinique (IREC), and Clinique Universitaire Saint-Luc, Université catholique de Louvain, Brussels, Belgium.
14
Department of Cardiovascular Sciences, Leuven University, Leuven, Belgium.

Abstract

Disturbed metabolism as a consequence of obesity and diabetes may cause cardiac diseases (recently highlighted in the cardiovascular research spotlight issue on metabolic cardiomyopathies).1 In turn, the metabolism of the heart may also be disturbed in genetic and acquired forms of hypertrophic cardiac disease. Herein, we provide an overview of recent insights on metabolic changes in genetic hypertrophic cardiomyopathy and discuss several therapies, which may be explored to target disturbed metabolism and prevent onset of cardiac hypertrophy.This article is part of the Mini Review Series from the Varenna 2017 meeting of the Working Group of Myocardial Function of the European Society of Cardiology.

PMID:
29912308
PMCID:
PMC6054261
DOI:
10.1093/cvr/cvy147
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Silverchair Information Systems Icon for PubMed Central
Loading ...
Support Center